Preeti Kanikarla
Overview
Explore the profile of Preeti Kanikarla including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
89
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Villarreal O, Xu Y, Tran H, Machado A, Prescod D, Anderson A, et al.
bioRxiv
. 2025 Feb;
PMID: 39896605
MAPK pathway inhibitors (MAPKi) are increasingly used in the treatment of advanced colorectal cancer, but often produce short-lived responses in patients. Although acquired resistance by mutations in tumors have been...
2.
Takeda M, Theardy M, Sorokin A, Coker O, Kanikarla P, Chen S, et al.
bioRxiv
. 2024 Aug;
PMID: 39211217
The therapeutic benefit of recently developed mutant KRAS (mKRAS) inhibitors has been limited by the rapid onset of resistance. Here, we aimed to delineate the mechanisms underlying acquired resistance to...
3.
Napolitano S, Woods M, Lee H, De Falco V, Martini G, Della Corte C, et al.
Clin Cancer Res
. 2023 Apr;
29(12):2299-2309.
PMID: 37040395
Purpose: Encorafenib + cetuximab (E+C) is an effective therapeutic option in chemorefractory BRAFV600E metastatic colorectal cancer (mCRC). However, there is a need to improve the efficacy of this molecular-targeted therapy...
4.
Parseghian C, Sun R, Woods M, Napolitano S, Lee H, Alshenaifi J, et al.
J Clin Oncol
. 2022 Nov;
41(3):460-471.
PMID: 36351210
Purpose: Acquired resistance to anti-epidermal growth factor receptor (EGFR) inhibitor (EGFRi) therapy in colorectal cancer (CRC) has previously been explained by the model of acquiring new mutations in , among...
5.
Ryan M, Coker O, Sorokin A, Fella K, Barnes H, Wong E, et al.
Cell Rep
. 2022 Jun;
39(12):110993.
PMID: 35732135
Although KRAS has long been considered undruggable, direct KRAS inhibitors have shown promising initial clinical efficacy. However, the majority of patients still fail to respond. Adaptive feedback reactivation of RAS-mitogen-activated...
6.
Pradhan G, Wu C, Lee J, Kanikarla P, Guo S, Yechoor V, et al.
Sci Rep
. 2017 Apr;
7(1):979.
PMID: 28428639
Orexigenic hormone ghrelin and anorexic hormone obestatin are encoded by the same preproghrelin gene. While it is known that ghrelin inhibits glucose-stimulated insulin secretion (GSIS), the effect of obestatin on...